ISSN: 1734-1922
Archives of Medical Science Special Issues
Current issue Archive Archives of Medical Science

Risk stratification in ACS
Biomarkers for outcomes following acute coronary syndromes

Ravi Karra
Richard C. Becker

Arch Med Sci 2010; 6, 1A: S 55–S 63
Online publish date: 2010/01/26
View full text Get citation
Mortality attributed to acute coronary syndromes (ACS) has declined steadily since 1968. Biomarkers, such as troponin, have contributed to the observed decline by improving diagnostic sensitivity and specificity, as well as by improving patient risk stratification. Emerging biomarkers, including BNP and CRP, may have additional roles in improving risk stratification following ACS. With an improved understanding of the pathophysiology of atherothrombosis, advanced technology, and an increased ability to efficiently screen and reliably measure molecular, cellular, and other blood-borne biomarkers, the overall role of biomarkers in clinical decision making is expected to expand exponentially. To this end, biomarkers will require strict standards for development, investigation, and validation in carefully designed clinical trials before being adopted into routine patient care. Here, we review established and emerging biomarkers for assessment and management of post-ACS outcomes.

biomarker, acute coronary syndrome, infarction

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.